A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

Epidermal growth factor receptor overexpression is associated with poor outcomes in urothelial carcinoma (UC). Cetuximab (CTX) exhibited an antitumor effect in in vivo UC models. The efficacy of gemcitabine/cisplatin (GC) with or without CTX in patients with advanced UC was evaluated.

[1]  Daniel J Sargent,et al.  Randomized Phase II Clinical Trials , 2014, Journal of biopharmaceutical statistics.

[2]  William Wheeler,et al.  Genome-wide association study identifies multiple loci associated with bladder cancer risk. , 2014, Human molecular genetics.

[3]  Kai Wang,et al.  Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy , 2014, Modern Pathology.

[4]  Dafydd G. Thomas,et al.  Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer , 2013, Molecular medicine.

[5]  Kai Wang,et al.  A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma , 2013, Clinical Cancer Research.

[6]  M. Rubin,et al.  Frequent truncating mutations of STAG2 in bladder cancer , 2013, Nature Genetics.

[7]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[8]  C. Sander,et al.  Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Gillatt,et al.  Thromboembolic events with cisplatin-based neoadjuvant chemotherapy for transitional cell carcinoma of urinary bladder. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Plimack,et al.  Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Tzai,et al.  Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis , 2012, Advances in urology.

[12]  M. Khorrami,et al.  E-cadherin expression as a prognostic factor in transitional cell carcinoma of the bladder after transurethral resection. , 2012, Urology journal.

[13]  M. Srougi,et al.  Immune expression of E-cadherin and α, β and γ-Catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas. , 2012, International braz j urol : official journal of the Brazilian Society of Urology.

[14]  S. Barni,et al.  Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Miyake,et al.  Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. , 2012, Urologic oncology.

[16]  Di Cui,et al.  [Analysis of N-E cadherin switch as an independent predictive parameter of bladder cancer survival outcomes]. , 2012, Zhonghua yi xue za zhi.

[17]  M. Day,et al.  EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. , 2012, Cellular signalling.

[18]  O. Omran.  CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma. , 2012, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[19]  F. Cheng,et al.  p130Cas, E‐cadherin and β‐catenin in human transitional cell carcinoma of the bladder: Expression and clinicopathological significance , 2011, International journal of urology : official journal of the Japanese Urological Association.

[20]  Maoyu Li,et al.  Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT‐like phenotype change and MMP‐9‐mediated degradation of E‐cadherin , 2011, Journal of cellular biochemistry.

[21]  Cynthia S. Johnson,et al.  Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. H. van der Kwast,et al.  FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy , 2010, PloS one.

[23]  C. Tangen,et al.  Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium , 2010, BJU international.

[24]  J. Machiels,et al.  A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma , 2009, Cancer.

[25]  D. Bajorin,et al.  A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  A. Ziaee,et al.  Mutations of RAS gene family in specimens of bladder cancer. , 2008, Urology journal.

[27]  P. Harari,et al.  Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members , 2008, Oncogene.

[28]  Xifeng Wu,et al.  Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells , 2008, Clinical Cancer Research.

[29]  S. Siena,et al.  First-line single-agent cetuximab in patients with advanced colorectal cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  H. Bojar,et al.  Heparin‐binding epidermal growth factor‐like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome , 2007, Cancer.

[31]  Marina Kriajevska,et al.  Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. , 2007, Urology.

[32]  E. Nexo,et al.  Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA‐damaging drug etoposide markedly increases apoptosis , 2007, BJU international.

[33]  N. Uluocak,et al.  The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma , 2007, International Urology and Nephrology.

[34]  H. Kume,et al.  The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. , 2006, European urology.

[35]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[36]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  O. Cussenot,et al.  Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. , 2005, European urology.

[38]  A. Feller,et al.  E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. , 2005, Oncology reports.

[39]  Arisan Serdar,et al.  The Prognostic Importance of E-cadherin and p53 Gene Expression in Transitional Bladder Carcinoma Patients , 2005, International Urology and Nephrology.

[40]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[41]  T. Wheeler,et al.  Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. , 2003, The Journal of urology.

[42]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[43]  M. Kattan,et al.  E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. , 2001, The Journal of urology.

[44]  T. Wheeler,et al.  E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. , 2001, Urology.

[45]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[46]  S. Eccles,et al.  Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[47]  A. Wells,et al.  Tumor invasion: role of growth factor-induced cell motility. , 2000, Advances in cancer research.

[48]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[49]  C. Dinney,et al.  Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  C. Busch,et al.  Expression of epidermal growth factor receptor in urinary bladder cancer metastases , 1998, International journal of cancer.

[51]  T. Tzai,et al.  Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. , 1997, Anticancer research.

[52]  J. Bosson,et al.  Expression of E-cadherin and alpha-,beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? , 1997, Invasion & metastasis.

[53]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[54]  D. Neal,et al.  Original Articles: Bladder Cancer , 1995 .

[55]  S. Kroft,et al.  Urinary bladder cancer: mechanisms of development and progression. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[56]  P. Lipponen,et al.  Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. , 1994, British Journal of Cancer.

[57]  P. Swanson,et al.  Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. , 1994, American journal of clinical pathology.

[58]  E. Messing.  Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. , 1990, Cancer research.

[59]  A. Harris,et al.  The epidermal growth factor receptor and the prognosis of bladder cancer , 1990, Cancer.

[60]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[61]  Visvanathan Kv,et al.  Preferential and novel activation of H-ras in human bladder carcinomas. , 1988 .

[62]  I. Summerhayes,et al.  Preferential and novel activation of H-ras in human bladder carcinomas. , 1988, Oncogene research.

[63]  M. Bennett,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS , 1985, The Lancet.

[64]  R. Frelick.  Cancer and leukemia group B (CALGB). , 1979, Delaware medical journal.

[65]  A. Harris.  Letter: Vitamin-C-induced hyperoxaluria. , 1976, Lancet.